Mexiprim, 50 mg/ml 5 ml 5 pcs

Mexiprim belongs to the heteroaromatic antioxidants.

It has a wide range of pharmacological activity: increases the body’s resistance to stress, shows anxiolytic effect, not accompanied by drowsiness and myorelaxant effect; has nootropic properties, prevents and reduces learning and memory disorders arising from aging and exposure to various pathogenic factors; has anticonvulsant effect; shows antioxidant and antihypoxic properties; increases attention concentration and performance; weakens the toxic effects of alcohol.

The drug improves brain tissue metabolism and blood supply, improves microcirculation and blood rheology, reduces platelet aggregation.

Stabilizes membrane structures of blood cells (erythrocytes and platelets). It has hypolipidemic effect, decreases the total cholesterol and low-density lipoproteins.

Mechanism of action of Mexiprim is due to its antioxidant and membrane-protective effect.

It inhibits lipid peroxidation, increases superoxidase activity, increases lipid-protein ratio, decreases membrane viscosity and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine) that increases their ability to bind to ligands, maintains structural and functional organization of biomembranes, neurotransport and improves synaptic transmission.

Mexiprim increases dopamine content in the brain.

Causes compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle in hypoxia with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Pharmacokinetics

Maximum concentration of Mexiprim in blood plasma is in the range of 50 to 100 ng/ml.

The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively.

Mexiprim in humans is extensively metabolized to form its glucuron-conjugated product.

On average over 12 hours 0.3% of unchanged drug and 50% as glucuronoconjugate of the administered dose are excreted with urine.

Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after drug administration.

Indicators of urinary excretion of Mexiprim and its conjugated metabolite have significant individual variability.

Indications

Active ingredient

Composition

Composition per 1 ml:

Ethylmethylhydroxypyridine succinate – 50 mg

Water for injection – up to 1 ml.

How to take, the dosage

Mexicaprim is administered intramuscularly or intravenously (by trickle or drip). Doses are adjusted individually.

During infusion method the drug should be diluted in physiological sodium chloride solution.

The treatment begins with a dose of 50-100 mg 1 to 3 times a day and the dose is gradually increased until therapeutic effect is achieved.

Mexiprim is slowly administered by jetting for 5-7 minutes, by drip – at the rate of 40-60 drops per minute. The maximum daily dose is not more than 800 mg.

In acute disturbances of cerebral circulation Mexiprim is used in combination therapy in the first 2-4 days by intravenous drip by 200-300 mg once a day and then intramuscularly by 100 mg three times a day. The therapy period is 10-14 days.

In patients with dyscirculatory encephalopathy in the decompensation phase Mexiprim should be administered intravenously by trickle or dropwise in the dosage of 100 mg 2-3 times a day during 14 days.

Then the drug is administered intramuscularly in doses of 100 mg 2-3 times a day during the next two weeks. For course prophylaxis of discirculatory encephalopathy the preparation is administered intramuscularly in dose of 100 mg 2 times a day during 10-14 days.

In case of light cognitive disorders in elderly patients and in case of anxious disorders the preparation is administered intramuscularly in daily dose 100-300 mg daily during 14-30 days.

In cases of alcohol withdrawal syndrome Mexiprim is administered in the dosage of 100-200 mg intramuscularly 2-3 times a day or intravenously dropwise 1-2 times a day during 5-7 days.

In acute intoxication with antipsychotic agents the drug is administered intravenously in the dosage of 50-300 mg daily during 7-14 days.

Interaction

Compatible with psychotropic drugs.

It increases the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), anti-Parkinsonian drugs (levodopa), reduces the toxic effects of ethyl alcohol.

Special Instructions

Contraindications

Acute hepatic and/or renal failure, hypersensitivity to the drug.

Children, pregnancy, breast-feeding – due to the lack of study of the drug action in these categories of patients.

Side effects

Overdose

Similarities